|Market Cap||6,869 Cr||EPS||-8.6||High||255.35|
|Stock P/E||0.0||Net Profit Margin||NA||Low||248|
|Market Cap||6,869 Cr||ROE||0.0%|
|P/B Ratio||-19.4||Dividend Yield||0.0%|
|Industry P/E||60.1||Book Value||-12.8|
About the Company
Sun Pharma Advanced Research Company (SPARC) is a clinical stage bio-pharmaceutical company focused on continuously improving standards of care for patients globally, through innovation in therapeutics and delivery. SPARC was formed in 2007 through a demerger from SUN PHARMA, a global leader in speciality generics. It strive to build an enduring innovation engine built on strong scientific execution, high value analytics and aggressive portfolio management. A robust mix of internal ideation and strategic partnering with academic innovators and bio-pharma entrepreneurs fuel engine with potentially high impact ideas.
The company partner with thought-leading clinicians across the world for ideas and access. Innovation through integration of partner knowledge and efficient internal execution shapes future. SPARC is a vibrant innovation community spread over three locations globally. It endeavour to develop a meritocracy which takes pride in continuous learning and re-invention. SPARC is a responsible public company committed to maintaining highest standards of ethics and transparency.
Business area of the company
The company is engaged in the pharmaceutical research and development. The company’s core focus is innovation and new product development for global markets. SPARC undertakes projects in research and technology for new chemical entities (NCE’s) or new molecules, and novel drug delivery systems (NDDS).
|Parent Organisation||Sun Pharma Advanced Research Company Ltd.||Managing Director|
|Company||52 Week||Market Price||P/E Ratio|
Frequently asked questions